Preliminary studies suggested that elevated levels of carbonic anhydrase IX (CAIX) in renal cell carcinoma patients conferred a better response to IL-2 therapy compared to patients with tumors demonstrating normal or low levels [89,90], but larger trials that included additional characteristics raised the possibility of more discriminating markers that remain under active investigation. Here, CA9 is linked to hereditary clear cell renal cell carcinoma.